87 related articles for article (PubMed ID: 19072641)
21. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?
Ingelman-Sundberg M; Cascorbi I
Clin Pharmacol Ther; 2016 May; 99(5):478-80. PubMed ID: 26874931
[TBL] [Abstract][Full Text] [Related]
23. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
24. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
26. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
27. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
28. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.
Buys TP; Chari R; Lee EH; Zhang M; MacAulay C; Lam S; Lam WL; Ling V
Genes Chromosomes Cancer; 2007 Dec; 46(12):1069-79. PubMed ID: 17726699
[TBL] [Abstract][Full Text] [Related]
29. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos AG; Kerr DJ; Herod J; Hodgkins L; Krajewski S; Reed JC; Young LS
Oncogene; 1995 Oct; 11(7):1217-28. PubMed ID: 7478541
[TBL] [Abstract][Full Text] [Related]
30. Identification of candidate methylation-responsive genes in ovarian cancer.
Menendez L; Walker D; Matyunina LV; Dickerson EB; Bowen NJ; Polavarapu N; Benigno BB; McDonald JF
Mol Cancer; 2007 Jan; 6():10. PubMed ID: 17254359
[TBL] [Abstract][Full Text] [Related]
31. Evolution of pharmacogenomics.
Somogy A
Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
[TBL] [Abstract][Full Text] [Related]
32. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
33. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
34. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation and personalized medicine.
Tang J; Xiong Y; Zhou HH; Chen XP
J Clin Pharm Ther; 2014 Dec; 39(6):621-7. PubMed ID: 25230364
[TBL] [Abstract][Full Text] [Related]
36. Update on drugs in advanced ovarian cancer.
O'Malley D
Clin Adv Hematol Oncol; 2020 Jun; 18(6):308-311. PubMed ID: 32649652
[No Abstract] [Full Text] [Related]
37. Correlation of anti-tumour drug resistance with epigenetic regulation.
Hayashi T; Konishi I
Br J Cancer; 2021 Feb; 124(4):681-682. PubMed ID: 33268818
[TBL] [Abstract][Full Text] [Related]
38. Improving cancer therapeutics by molecular profiling.
Corchero J; Fernández-Salguero PM
Curr Drug Metab; 2005 Dec; 6(6):553-68. PubMed ID: 16379669
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics.
Ross JS; Schenkein DP; Kashala O; Linette GP; Stec J; Symmans WF; Pusztai L; Hortobagyi GN
Adv Anat Pathol; 2004 Jul; 11(4):211-20. PubMed ID: 15220824
[TBL] [Abstract][Full Text] [Related]
40. Accurate prediction and elucidation of drug resistance based on the robust and reproducible chemoresponse communities.
Dai E; Wang J; Yang F; Zhou X; Song Q; Wang S; Yu X; Liu D; Yang Q; Dai H; Jiang W; Ling H
Int J Cancer; 2018 Apr; 142(7):1427-1439. PubMed ID: 29143332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
